DOLUTEGRAVIR SODIUM AND LAMIVUDINE

3600 reported adverse events

Drug classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking DOLUTEGRAVIR SODIUM AND LAMIVUDINE:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 1096
1 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 256
2 PRODUCT DOSE OMISSION IN ERROR 224
3 PRODUCT USE ISSUE 195
4 ANXIETY 155
5 PAIN 142
6 DRUG INEFFECTIVE 137
7 RASH 126
8 FATIGUE 122
9 VIRAL LOAD INCREASED 121
See all common reactions for DOLUTEGRAVIR SODIUM AND LAMIVUDINE

DOLUTEGRAVIR SODIUM AND LAMIVUDINE is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYSTOSTOMY 15 0.2679
1 CD4 LYMPHOCYTE PERCENTAGE DECREASED 4 0.0909
2 HORMONE-DEPENDENT PROSTATE CANCER 5 0.0714
3 MONKEYPOX 15 0.0543
4 BLOOD HIV RNA INCREASED 82 0.0452
5 HYPERANDROGENISM 4 0.0426
6 CONGENITAL GENITAL MALFORMATION 6 0.0375
7 PRODUCT USE IN UNAPPROVED THERAPEUTIC ENVIRONMENT 32 0.0366
8 INTERFERON GAMMA RELEASE ASSAY POSITIVE 6 0.0366
9 SYPHILIS 25 0.0344
See all enriched reactions for DOLUTEGRAVIR SODIUM AND LAMIVUDINE